CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
8-Chloroadenosine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02509546
NCT02509546Phase 2Completed

A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical Center·interventional·Posted Jul 28, 2015·Updated Dec 5, 2023

In Brief

A Phase 2 clinical trial evaluating 8-Chloroadenosine, Laboratory Biomarker Analysis, and 1 other intervention for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as 8-chloroadenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 28, 2015
Enrollment StartSep 2, 2015
Primary CompletionMar 9, 2021
Study CompletionMar 16, 2021
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 10.9 years ago

Interventions

8-Chloroadenosinedrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies

Pharmacological Studyother

Correlative studies